STRO

#2802
Sutro Biopharma, Inc.
35.8000 USD
+6.58%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
35.6777
35.9500
年范围
16.7400
36.0000
日变化
+6.58%
每月变动
+46.54%
6个月变化
+105.87%
年变化
+105.87%
前一天收盘价
33.5900
开盘价
35.9500
最低价
35.6777
High
35.9500
交易量
5
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 593.1071 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry 生物技术
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-0.51
市销率
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

新闻